Innovative Gene Therapy Partnership to Enhance Hemophilia A Treatment Options for Patients in China Belief BioMed and Grand Life Sciences have entered an exclusive partnership to bring innovative gene therapy for hemophilia A to patients in China, aiming to transform treatment options.

Innovative Gene Therapy Partnership to Enhance Hemophilia A Treatment Options for Patients in China #China #Shanghai #Hemophilia_A #Belief_BioMed #Grand_Life_Sciences

Belief BioMed's BBM-H901 Receives Approval for Hemophilia Treatment in Macao Belief BioMed has achieved a milestone with the approval of BBM-H901 in Macao, marking a significant expansion in hemophilia B treatment options. This innovative gene therapy offers hope to patients in the region.

Belief BioMed's BBM-H901 Receives Approval for Hemophilia Treatment in Macao #China #Macao #Hemophilia_B #Belief_BioMed #BBM-H901

Belief BioMed Celebrates FDA IND Acceptance for AskBio's Gene Therapy Aimed at Pompe Disease Treatment Belief BioMed proudly announces AskBio's FDA IND acceptance for AB-1009, a gene therapy for late-onset Pompe disease, marking a vital milestone.

Belief BioMed Celebrates FDA IND Acceptance for AskBio's Gene Therapy Aimed at Pompe Disease Treatment #Shanghai #USA #gene_therapy #Belief_BioMed #AskBio

China Approves First Hemophilia B Gene Therapy: BBM-H901 by Belief BioMed and Takeda Belief BioMed and Takeda China have announced the official approval of BBM-H901, the first gene therapy for hemophilia B in China, transforming treatment options for patients.

China Approves First Hemophilia B Gene Therapy: BBM-H901 by Belief BioMed and Takeda #China #Shanghai #Belief_BioMed #Takeda_China #BBM-H901